Embed Size (px)
Citation preview
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
Baseline clinical characteristics
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
Laboratory data and endothelial function during a fasting state before and after treatment for 4 weeks
in the ezetimibe and control groups
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
(A–C) Postprandial changes in serum TG, RLP-C and apoB-48 levels and the AUC for postprandial serum TG, RLP-C and apoB-48 levels before and after treatment for 4 weeks in the ezetimibe and control groups (D) Postprandial changes in %FMD and changes in maximum reduction of %FMD after the cookie test (max Δ%FMD) before and after treatment for 4 weeks in the ezetimibe and control groups
Open bar indicates ezetimibe group; solid bar, control group Data are expressed as mean ± SE. *P < 0.05, vs. before treatment
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
Postprandial changes in serum TG levels and the AUC for postprandial serum TG levels before and after treatment
for 4 weeks in the ezetimibe and control groups
(open bar indicates ezetimibe group; solid bar, control group)Data are expressed as mean ± SE. *P < 0.05, vs. before treatment
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
Postprandial changes in serum RLP-C levels and the AUC for postprandial serum RLP-C levels before and after
treatment for 4 weeks in the ezetimibe and control groups
(open bar indicates ezetimibe group; solid bar, control group)Data are expressed as mean ± SE. *P < 0.05, vs. before treatment
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
Postprandial changes in serum apoB-48 levels and the AUC for postprandial serum apoB-48 levels before and after
treatment for 4 weeks in the ezetimibe and control groups
(open bar indicates ezetimibe group; solid bar, control group)Data are expressed as mean ± SE. *P < 0.05, vs. before treatment
Yunoki K et al. Atherosclerosis 2011 Epub Apr 22
Postprandial changes in %FMD and changes in maximum reduction of %FMD after the cookie test
(max Δ%FMD) before and after treatment for 4 weeks in the ezetimibe and control groups
Data are expressed as mean ± SE. *P < 0.05, vs. before treatment
